Norris Perne & French LLP MI lessened its holdings in AbbVie Inc. (NYSE:ABBV) by 2.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 29,712 shares of the company’s stock after selling 625 shares during the period. Norris Perne & French LLP MI’s holdings in AbbVie were worth $2,154,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in ABBV. State Street Corp grew its holdings in shares of AbbVie by 2.4% during the first quarter. State Street Corp now owns 72,969,530 shares of the company’s stock worth $4,754,696,000 after purchasing an additional 1,696,042 shares during the last quarter. Wedge Capital Management L L P NC bought a new stake in shares of AbbVie during the first quarter worth about $46,744,000. Bank of Nova Scotia grew its holdings in shares of AbbVie by 297.9% during the first quarter. Bank of Nova Scotia now owns 606,321 shares of the company’s stock worth $39,507,000 after purchasing an additional 453,955 shares during the last quarter. Skandinaviska Enskilda Banken AB publ grew its holdings in shares of AbbVie by 42.3% during the first quarter. Skandinaviska Enskilda Banken AB publ now owns 1,202,483 shares of the company’s stock worth $78,354,000 after purchasing an additional 357,353 shares during the last quarter. Finally, AQR Capital Management LLC grew its holdings in shares of AbbVie by 58.6% during the first quarter. AQR Capital Management LLC now owns 940,824 shares of the company’s stock worth $61,304,000 after purchasing an additional 347,710 shares during the last quarter. Hedge funds and other institutional investors own 68.25% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/23/abbvie-inc-abbv-holdings-cut-by-norris-perne-french-llp-mi.html.

Several analysts have recently weighed in on ABBV shares. Zacks Investment Research cut AbbVie from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. Vetr upgraded AbbVie from a “hold” rating to a “buy” rating and set a $74.86 price target on the stock in a report on Thursday, July 6th. Jefferies Group LLC restated a “buy” rating and set a $94.00 price target (up from $92.00) on shares of AbbVie in a report on Monday, July 17th. Deutsche Bank AG restated a “hold” rating and set a $66.00 price target (up from $65.00) on shares of AbbVie in a report on Monday, July 17th. Finally, Credit Suisse Group restated a “neutral” rating and set a $74.00 price target (up from $65.00) on shares of AbbVie in a report on Thursday, July 20th. Eight analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $92.79.

AbbVie Inc. (NYSE:ABBV) opened at 96.10 on Monday. The firm has a 50-day moving average price of $88.06 and a 200 day moving average price of $73.89. AbbVie Inc. has a 52 week low of $55.06 and a 52 week high of $98.26. The firm has a market capitalization of $153.19 billion, a price-to-earnings ratio of 23.64 and a beta of 1.51.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, July 28th. The company reported $1.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.02. The business had revenue of $6.94 billion for the quarter, compared to analyst estimates of $6.93 billion. AbbVie had a return on equity of 150.27% and a net margin of 24.77%. AbbVie’s revenue for the quarter was up 7.6% compared to the same quarter last year. During the same period last year, the company earned $1.26 EPS. On average, equities research analysts forecast that AbbVie Inc. will post $5.53 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th will be given a $0.64 dividend. The ex-dividend date of this dividend is Thursday, October 12th. This represents a $2.56 dividend on an annualized basis and a dividend yield of 2.66%. AbbVie’s dividend payout ratio is currently 62.90%.

In other news, Chairman Richard A. Gonzalez sold 193,131 shares of AbbVie stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $71.00, for a total value of $13,712,301.00. Following the sale, the chairman now directly owns 469,623 shares in the company, valued at approximately $33,343,233. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Edward J. Rapp acquired 4,000 shares of the business’s stock in a transaction dated Monday, July 31st. The stock was acquired at an average price of $70.45 per share, for a total transaction of $281,800.00. Following the completion of the transaction, the director now owns 15,498 shares in the company, valued at approximately $1,091,834.10. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 379,890 shares of company stock worth $27,187,817. Corporate insiders own 0.23% of the company’s stock.

AbbVie Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Stock Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related stocks with our FREE daily email newsletter.